期刊文献+

观察索拉非尼治疗晚期肾癌期间高血压的发生及其处理 被引量:2

暂未订购
导出
摘要 目的探讨索拉菲尼治疗晚期肾癌期间引发高血压几率,以及降压治疗对索拉菲尼疗效的预测关系。方法选择该院肿瘤科收治的晚期肾癌患者28例,给予所有患者索拉菲尼口服,统计服药期间高血压发生率。并根据高血压分级标准对高血压进行分级,观察高血压的发生与索拉非尼疗效的关系。结果 28例晚期肾癌患者服用索拉菲尼后,总有效率为82.14%,引发高血压例数为8(28.57%)例,包括1级高血压患者2例,2级4例,3级2例,无4级及高血压危象出现,且通过生活指导、药物治疗后,血压控制在标准范围内,血压稳定,未出现索拉菲尼减量与停药病例。且索拉非尼疗效与高血压发生率关系对比,差异无统计学意义(P>0.05)。结论索拉菲尼治疗晚期肾癌期间极易引发高血压,但均为轻中度高血压,且均可平稳降压,不会导致索拉非尼减量与停药,且高血压发生与索拉菲尼疗效无直接关系。
出处 《中外医疗》 2013年第21期82-82,84,共2页 China & Foreign Medical Treatment
  • 相关文献

参考文献5

二级参考文献69

  • 1陈雯洁,俞茂华.老年人认知功能损害的危险因素[J].中华老年多器官疾病杂志,2005,4(2):146-149. 被引量:30
  • 2Chu D, Lacouture ME, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and metaanalysis. Acta Oncol, 2008, 47: 176-186.
  • 3Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 2007, 12: 426-437.
  • 4Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol, 2007, 18: 1117- 1125.
  • 5Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol, 2006, 11: 209-213.
  • 6Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res, 2006, 12:7271-7278.
  • 7Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib., novel targeted therapies for renal cell cancer. Pharmacotherapy, 2007, 27: 1125-1144.
  • 8Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356: 125-134.
  • 9Procopio G, Verzoni E, Gevorgyan A, et al. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology, 2007, 73: 204-209.
  • 10Ratain MJ, Eisen T, Stadler WM, et al. Phase Ⅱ placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24: 2505-2512.

共引文献19

同被引文献10

  • 1赵欣.索拉非尼治疗晚期肾癌临床研究[J].中国协和医科大学学报,2010,13(2): 1254-1256.
  • 2Zhang H, Dong B, Lu J J, et al. Efficacy of sorafenib on me-ta-static renal cell carcinoma in Asian patients:Results from a mnlticenter study[ J]. BMC Cancer,2009,9 (16) :249.
  • 3Escudier B,Eison T, Stadler WM, et al. TARGET Study G- roup. Sorafenib in advanced clear-cell renal-cell carcinoma [J]. N Engl J Med,2007,35(6) :125-134.
  • 4Escudier B,Eisen T, Stadler WM, et al. Sorafenib for treat- ment of renal cell carcinflma:Final efficacy and safety re- suhs of the phase m treatment approaches in renal cancer global evaluation trial [J ]. J Clin Oncol, 2009,27 ( 20 ) : 3312-3318.
  • 5Clark JW, Eder JP, Ryau D, et al. Safety and pharmacoki- netics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors [ J ]. Clin Cancer Res ,2005,11 ( 15 ) :5472-5480.
  • 6周爱萍,何志嵩,于世英,张沂平,杜春霞,孙永昆,石远凯,王金万,那彦群,孙燕.索拉非尼治疗转移性肾癌的临床研究[J].中华泌尿外科杂志,2009,30(1):10-14. 被引量:54
  • 7张海梁,叶定伟,姚旭东,张世林,戴波,沈益君,朱耀,朱一平,施国海,马春光.索拉非尼治疗晚期肾癌的不良反应和处理方法[J].中华泌尿外科杂志,2009,30(1):32-35. 被引量:9
  • 8周开良,朱泽文.索拉菲尼与生物化疗治疗转移性肾癌的疗效观察[J].中国现代医学杂志,2011,21(1):149-151. 被引量:9
  • 9商迪,尹胜杰.索拉非尼治疗晚期肾癌的近远期效果[J].中国卫生标准管理,2015,6(2):65-66. 被引量:1
  • 10吴平平,朱华云,陈嘉,孙小峰.索拉非尼治疗晚期肾癌37例疗效分析[J].江苏医药,2015,41(2):203-204. 被引量:3

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部